Marker Therapeutics, Inc.

Tagged: polystart

TapImmune to Present at World Vaccine & Immunotherapy Congress West Coast

Chairman and Strategic Advisor Glynn Wilson, Ph.D., and Senior Director of Molecular Biology & Virology Robert Florkiewicz, Ph.D., will give an oral presentation titled, “Increasing the potency of DNA-based immunotherapies using PolyStart™ peptide expression system,” at the World Vaccine & Immunotherapy Congress West Coast, held Thursday, November 30 – December 1, 2017, at the Loews Coronado Bay Resort in San Diego, CA.

Read More

TapImmune Expands Intellectual Property On PolyStartTM Platform For Use In Next-Generation T-Cell Vaccines

TapImmune, Inc. (NASDAQ: TPIV) today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application titled, “Chimeric nucleic acid molecules with non-AUG initiation sequences and uses thereof.”

Read More

TapImmune To Present At The LD Micro IX Main Event, December 6-8, 2016

TapImmune, Inc. (NASDAQ: TPIV) will provide a corporate presentation at the LD Micro IX Main Event on Tuesday, December 6, 2016 at 12:00 p.m. (PST). The conference will take place at the Luxe Sunset Boulevard Hotel…

Read More

TapImmune Receives Notice of Allowance on U.S. Patent Claims for PolyStart – Next-Generation T-Cell Vaccine

…Proprietary DNA Expression Vector Technology Developed at TapImmune’s Laboratories

PolyStart to Move into Clinical Trials and Expand TapImmune‘s Development Pipeline

TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based immunotherapeutic vaccines for the treatment of cancer, including metastatic cancer, announced today that it has received a Notice of Allowance from the U.S.

Read More

TapImmune Inc. is Pleased to Announce the Filing of New Intellectual Property Surrounding its Novel and Proprietary Platform Expression System PolyStart™

…New Technology Significantly Enhances the Presentation of Desired Peptides on the Surface of Cells for Targeting to the Immune System

SEATTLE–(BUSINESS WIRE)–

TapImmune Inc. (TPIVD), a clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease has filed a new patent application for a novel technology platform designed to enhance the visibility of cancer or infected cells to a patient’s immune system, a critical aspect of an effective vaccine.

Read More